The first standard application due date for this FOA is February 5, 2019.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.
Applications that do not comply with these instructions may be delayed or not accepted for review.
The purpose of this Funding Opportunity Announcement (FOA) is to support the development and optimization of tasks and/or measures for constructs pertaining to functional domains of behavior or cognitive/affective processes, for use in laboratory or population-based studies and clinical trials outcomes. This FOA encourages research that will result in the availability of tasks and measures of constructs that demonstrate: (1) good validity as a measure of a specific construct; (2) robust measurement properties; and (3) suitability for use with individuals who vary widely in age, ability, and/or severity of disorder. Because there are some constructs for which there are well-validated tasks/measures already available and others for which there are few standardized tasks/measures, ?candidate tasks/measures should be selected based on an analysis of the existing tools for assessing the construct(s) of interest and an assessment of the methodological and psychometric issues that are in need of further empirical work. Highest priority will be given to applications that target constructs with the greatest need for optimized measurement tools. In addition to the inherent value of having validated and psychometrically sound measurements, the tasks and measures will be evaluated for their potential to serve as common data elements for sharing and harmonizing data across multiple studies and data sets.
Research Objectives and Scope
This FOA encourages research projects to develop new tasks and measures or to optimize existing tasks and measures for functional behavioral constructs. Tasks and measures could include self-report tools, behavioral tasks, physiological measures, or neuroimaging protocols. Their properties should allow use with diverse research participants in a consistent manner. Optimally, tasks should provide a behavioral output, but for some constructs, a physiological or neuroimaging paradigm that does not involve behavioral responses may be appropriate. A single task/measure may yield multiple outputs or data elements, which may be associated with different constructs or units of analysis. It is important, however, that the specific relationship between individual outputs or data elements and the constructs be defined and determined. Because the development status of different tasks and measures varies, the nature and scope of proposed projects is expected to vary, with some projects focused on early stage development of novel tasks/measures and other focused on optimizing existing tasks. The intended use of the test should be considered in designing research projects; some tasks may be intended for use in high-throughput phenotyping or screening purposes, and others may require specialized equipment and procedures. Stages of measurement development covered in this announcement include validation, assessment of measurement characteristics, standardization of administration procedures/parameters, and collection of normative data.
Given the primary importance of validity in assessment methods, applications must provide either a review of existing evidence of strong validity for the task as a measure of an indicated construct or should include plans to test the construct validity of the task. This may be accomplished by tests of convergent, divergent, concurrent, and/or predictive validity. Evidence of validity can also be provided by data from relevant clinical populations, imaging studies with normal and clinical samples, and/or pharmacological or behavioral manipulation studies involving animal or human models.
Task parameters should be empirically tested in order to optimize measurement characteristics (i.e., psychometric properties), including such considerations as internal reliability, test-retest reliability, alternate forms reliability, stability, practice effects, ceiling/floor (i.e., range) effects, and optimal task length and difficulty. The degree to which these characteristics vary in clinical versus healthy populations is also relevant.
Standardization of administration procedures and parameters (e.g., number of trials, stimulus characteristics) enables examiners in diverse settings to implement tasks in a consistent manner. Applicants should address any administration and scoring difficulties that may limit usability. The standardization process should include considerations of burden and practicality and may include establishing specific stimulus or item sets and administration procedures including response options and presentation parameters, with appropriate attention to potential variation needed as a function of population, setting, or stimulus presentation hardware. Any modifications needed to allow use of tasks across different age groups and ability levels should be standardized. Documentation and ?instructions should allow implementation of the task(s) by new users.
Normative data are necessary for the interpretation of performance/scores across administration settings. For the purposes of establishing normative data, the participant sample should be diverse with regard to age, gender, ethnicity, education, and socioeconomic status. In particular, applicants should power studies to evaluate sex differences and sex-specific effects, in accord with current NIH priorities on sex as a biological variable (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-102.html).
Successful applications will identify a true gap in measurement tools for a specific construct or ?constructs. Applications proposing to study a measure for a construct that already has several useable tasks will not be considered high priority for funding. Applicants should explain the details of the gap in available methods and how the proposed work will address the shortcoming. This should be accompanied by specific descriptions of the data that will be collected and what criteria will be used to evaluate if the characteristics are considered robust enough for use. An application may focus on a single task/measure or more than one task/measure.
Interests of Participating NIH Institutes, Centers and Offices
The National Institute of Mental Health (NIMH) is interested in applications that pertain to the Research Domain Criteria (RDoC) initiative (https://www.nimh.nih.gov/research-priorities/rdoc/index.shtml ). The RDoC matrix includes five major domains of function (Negative Valence Systems, Positive Valence Systems, Cognitive Systems, Systems for Social Processes, and Arousal/Regulatory Systems), each with several inter-related constructs (https://www.nimh.nih.gov/research-priorities/rdoc/constructs/rdoc-matrix.shtml ). There are some constructs for which standardized tasks and measures have been identified and others for which no standardized task or measure exists. A workgroup of the National Advisory Mental Health Council (NAMHC) was convened in April, 2016 to evaluate tasks and measures for each RDoC construct (see the workgroup’s final report, https://www.nimh.nih.gov/about/advisory-boards-and-groups/namhc/reports/rdoc_council_workgroup_report_153440.pdf ). While this document is not a comprehensive review of RDoC-related tasks and measures, it does contain information regarding the gaps in the current recommendations for tasks and measures, as well as specific examples of tasks that require further evaluation. Applicants to this FOA are encouraged to consult the report as they formulate their research plans.
As RDoC is considered to be an evolving research framework that supports continual updating on the basis of new information, investigators are encouraged to submit applications intended to develop tasks/measures that assess current RDoC constructs or modified conceptions of current constructs. For modified constructs, applicants should provide supportive information consistent with the established criteria for developing RDoC constructs, i.e., (1) evidence for a functional dimension of behavior/cognition, (2) evidence for a neural circuit/system predominantly involved in implementing the behavior, and (3) relevance for psychopathology. These three construct criteria are particularly relevant for applications which will use computational approaches that employ data-driven methods to assess current or modified constructs.
Tasks/measures may be developed either for traditional laboratory/clinic settings, or for population-based studies that involve self-administration via mobile or web-based apps. Priority will be given to tasks for which versions can be developed that show potential validity in either type of setting, although applicants may focus on one or the other setting for initial task development.
The RDoC framework includes an emphasis upon neurodevelopmental factors that affect psychopathology, and also the broad range of environmental influences, both harmful and protective, that interact with neurodevelopment to confer risk or resilience. Given this emphasis, the development and/or validation of tasks/measures that can be scaled for appropriate use across a broad range of development, or that target critical periods of development, are of high priority. (For example, many measures in the NIH Toolbox, http://www.nihtoolbox.org/Pages/default.aspx , are standardized from ages 3 to 85.) However, it is recognized that for many RDoC constructs (e.g., for assessing fear or reward-related behavior), it is not possible to develop scaled version of the same task across age ranges; further, it is highly expensive to validate the scaling of a task across the entire life span. For these reasons, applicants may confine the focus of the research plan to a particular, justifiable age range. However, applicants should address the potential age range for which a task/measure might be scaled and address any future plans to expand the age range of validation. Development of tasks that target children of particular ages, or that could readily be scaled across the range of childhood, is particularly encouraged.
Relevant research topics include, but are not limited to:
Development of variants of existing task(s)/measure(s) that are optimized for use in a novel setting or for a new clinical research purpose; for example, development and testing of parallel versions of a task that can be used for high-throughput phenotyping for screening purposes and for intensive, lab-based research.
Development of tasks/measures for realms of behavior that are computationally definable, and conducted within the scope of a theoretical framework that is sufficiently precise to make quantitative predictions about how computational processes (neural and/or psychological) can result in particular aspects of behavior;
Direct comparisons of a range of administration parameters and analysis of the effects on the test’s measurement characteristics.
Development of standardized stimuli for an existing task in order to enhance usability across age groups or level of ability and/or as a repeated measure with psychometrically equivalent alternate forms.
The collection of normative data from a broad population and development of methods to convert raw scores into a common scale that can be interpreted in a standardized way. This stage of task development is most appropriate for tasks and measures for which reliability and validity have been established
Projects that would not be supported by NIMH under this announcement include:
Development or optimization of tests that are only suitable for animal research; however, development of tasks that have animal analogs is encouraged.
Applications that propose to modify the current structure of the RDOC matrix by suggesting new RDoC constructs, subconstructs, domains, or units of analysis. Please note that suggested changes to the RDoC matrix may be submitted to the RDoC Unit via RDocAdmin@mail.nih.gov and that investigators may submit investigator-initiated applications to study new constructs. Criteria for RDoC constructs are detailed here.
Applications that propose to study tests that are designed only for use with specific DSM or ICD diagnostic categories.
Projects that ONLY use existing data; while it would be appropriate, and encouraged, to include aims that involve aggregation and/or reanalysis of existing data, analysis of existing data should not be the sole focus of the application.
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is interested in tasks and measures of functional domains that are pertinent to alcohol use. NIAAA has established the Addictions Neuroclinical Assessment (ANA) as a package of tests and measures that are grounded in three neuroscience domains relevant for addictions, and which share significant overlap with RDoC. These domains comprise Incentive Salience, Negative Emotionality, and Executive Function. The NAMHC workgroup report described above identifies tasks that are relevant for these domains and for studying alcohol use disorder (AUD) and related constructs. For example, measures to assess Executive Function and Negative Emotionality overlap with Cognitive Systems and Negative Valence Systems, respectively. Because the NAHMC report did not include AUD, it does not identify aspects directly related to Incentive Salience, i.e., increased salience for alcohol and related cues. Thus, tasks that measure this domain are of specific relevance to the NIAAA.
In addition to measures focused on Incentive Salience, and the relevant research topics described under point 2 above, NIAAA is particularly interested in the following:
Projects focused on existing measures that have not been evaluated in patients with AUD and that test these measures in this population. For example, there may be different clinical considerations or normative data for use among patients with AUD as compared to healthy volunteer groups or patients with psychotic disease.
Identification of tasks that may be used repeatedly over time, i.e., are less sensitive to practice effects, and which are relevant for understanding changes in the ANA domains during acute and protracted withdrawal and recovery from AUD.
Additional testing of tasks that may be used in different age groups, e.g., with children, adolescents, and finally, adults, to understand risk factors for development and maintenance of AUD as measured by the same tasks. If using the same tasks is not feasible, direct comparison of tasks that assess the same domains/subdomains of function, e.g., visuospatial functioning, hypohedonia, etc. in different age groups would also be useful.
Evaluation of measures that may be used to predict recovery and relapse among patients with AUD, and measures that may be used to determine clinical trials outcomes.
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:
Buttons to access the online ASSIST system or to download application forms are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.
For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to:
All instructions in the SF424 (R&R) Application Guide must be followed.
Investigators: The investigative team should include individuals with expertise in assessment development, psychometrics, and, where relevant, computational modeling and/or neurocircuitry.
Innovation: The application should propose to develop a task/measure that addresses a true gap in measurement tools for a specific construct or constructs.?
Approach: The application should focus on optimization of selected task(s)/measures(s) for use in a diverse patient group and/or in individuals who span the illness/health dimension. While studies focused on the initial development of innovative new tasks/measures may recruit primarily healthy subjects, the sample must include a sufficient range of performance to provide evidence for the feasibility of the task in studies of patients with mental or substance-use disorders. Task(s)/measure(s) should have a strong theoretical and/or empirical relationship to one or more functional behavioral construct(s). The application should include a summary of existing evidence for construct validity or a plan to test for construct validity
The following modifications also apply:
If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.
See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov
Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday , the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement .
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues. For assistance with application submission, contact the Application Submission Contacts in Section VII.
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.
Important Update: See NOT-OD-18-228 for updated review language for due dates on or after January 25, 2019.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person’s race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.
In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 “Federal awarding agency review of risk posed by applicants.” This provision will apply to all NIH grants and cooperative agreements except fellowships.
For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see http://www.hhs.gov/ocr/civilrights/resources/laws/revisedlep.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html; and http://www.hhs.gov/ocr/civilrights/understanding/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 – Award Term and Conditions for Recipient Integrity and Performance Matters.
Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading forms and application packages)
Contact Center Telephone: 800-518-4726
GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.